Feb-15-19 07:35AM | Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit New Research Emphasizes Economic Growth GlobeNewswire +6.34% |
Feb-10-19 11:22PM | Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT Thomson Reuters StreetEvents |
Feb-06-19 08:43PM | Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript Motley Fool |
05:10PM | Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates Zacks |
04:07PM | Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot Associated Press |
04:01PM | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018 Business Wire |
Jan-30-19 10:31AM | Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy? Zacks |
Jan-22-19 12:09PM | Do You Like Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At This P/E Ratio? Simply Wall St. |
08:00AM | Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018 Business Wire |
Jan-18-19 06:16PM | Edited Transcript of ENTA earnings conference call or presentation 26-Nov-18 9:30pm GMT Thomson Reuters StreetEvents |
Jan-03-19 08:00AM | Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference Business Wire |
Dec-20-18 08:00AM | Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire |
Dec-15-18 11:23AM | Here is What Hedge Funds Think About Enanta Pharmaceuticals Inc (ENTA) Insider Monkey |
Dec-05-18 10:28AM | Is Enanta Pharmaceuticals Incs (NASDAQ:ENTA) CEO Pay Fair? Simply Wall St. |
Nov-29-18 04:48PM | Enanta Pharmaceuticals Inc (ENTA) Files 10-K for the Fiscal Year Ended on September 30, 2018 GuruFocus.com |
Nov-26-18 07:34PM | Enanta Pharmaceuticals Inc (ENTA) Q4 2018 Earnings Conference Call Transcript Motley Fool |
04:16PM | Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot Associated Press |
04:01PM | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 Business Wire |
Nov-19-18 10:30AM | Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy? Zacks |
Nov-13-18 11:40AM | Enanta Announces that AbbVies MAVYRET (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis Business Wire |
11:30AM | AbbVie's MAVYRET (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis PR Newswire |
Nov-07-18 10:10AM | Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals (ENTA) Zacks |
Oct-29-18 07:30AM | Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 Business Wire -5.95% |
Oct-26-18 08:15AM | Report: Developing Opportunities within Assured Guaranty, Potbelly, Enanta Pharmaceuticals, Seagate Technology, Ctrip.com International, and CyberArk Software Future Expectations, Projections Moving into 2018 GlobeNewswire |
Oct-23-18 07:30AM | Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus Business Wire |
Oct-11-18 01:31PM | How Good Is Enanta Pharmaceuticals Inc (NASDAQ:ENTA), When It Comes To ROE? Simply Wall St. |
Oct-05-18 11:00AM | Liver Cancers Rising - Stocks to Watch ACCESSWIRE |
Sep-25-18 08:45AM | Recent Analysis Shows Enanta Pharmaceuticals, Multi-Color, Otter Tail, Franklin Resources, CubeSmart, and EnPro Industries Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
Sep-05-18 07:30AM | Enanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium Business Wire |
Sep-04-18 12:01AM | Edited Transcript of ENTA earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents |
Aug-27-18 04:01PM | Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire |
Aug-13-18 06:00AM | Why Enanta Stock Is Still a Strong Buy With Huge Upside InvestorPlace -7.46% |
Aug-07-18 05:35PM | Enanta Pharmaceuticals (ENTA) Q3 Earnings and Revenues Top Estimates Zacks -8.48% |
04:32PM | Enanta Pharmaceuticals: Fiscal 3Q Earnings Snapshot Associated Press |
04:01PM | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018 Business Wire |
Aug-02-18 10:08AM | Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA) Zacks |
Jul-16-18 07:30AM | Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018 Business Wire |
Jun-27-18 10:39AM | Achieve Life Sciences' Shares Rise on Positive Clinical Data Zacks |
Jun-15-18 02:39PM | 2 Stable and 2 Speculative Biotech Stocks to Buy InvestorPlace |
Jun-12-18 07:30AM | Enanta Pharmaceuticals Recognizes the 1st International NASH Day Business Wire -5.10% |
Jun-07-18 08:10AM | Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics ACCESSWIRE |
Jun-01-18 08:38AM | Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon Zacks |
07:30AM | Enanta Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Presentation to be Webcast on June 12 at 9:30 A.M. GMT Business Wire |
May-29-18 05:45PM | Bayer's Generic Competition, Pipeline Setback Issues Remain Zacks |
08:10AM | Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire |
May-23-18 03:05PM | Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y Zacks |
May-21-18 11:09AM | AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia Zacks |
May-18-18 03:21PM | Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study Zacks |
May-17-18 10:09AM | Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion Zacks |
May-16-18 11:00AM | Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study Zacks |
May-15-18 10:45AM | Roche's Actemra Gets FDA Nod for Subcutaneous Formulation Zacks |
May-14-18 01:41PM | Edited Transcript of ENTA earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents |
May-11-18 05:09PM | Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat Zacks |
09:42AM | Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss Zacks |
05:59AM | Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up Zacks |
May-10-18 12:35PM | Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses Zacks |
10:41AM | Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus Zacks |
10:29AM | VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters Zacks |
May-08-18 04:44PM | Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot Associated Press |
04:00PM | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2018 Business Wire |
06:59AM | Calculating The Intrinsic Value Of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Simply Wall St. |
May-07-18 09:12AM | ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat Zacks |
Apr-24-18 09:31AM | This Small Biotech Is Building on a Surprising Success Motley Fool |
07:30AM | Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2018 Business Wire |
Apr-16-18 07:40AM | Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH ACCESSWIRE |
Apr-12-18 02:00AM | Enanta to Present New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH at The International Liver Congress 2018 Business Wire |
Apr-09-18 05:15PM | FDA Okays Label Expansion of Pacira's Exparel's, Stock Up Zacks |
Apr-06-18 06:32PM | Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why Zacks |
05:35PM | Novo Nordisk Obtains Licence for Sickle Cell Disease Program Zacks |
Apr-05-18 08:41AM | Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session Zacks |
Apr-04-18 11:15AM | Bio-Path Leukemia Combo Study Shows Positive Early Data Zacks |
07:50AM | Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire |
Apr-03-18 03:23PM | Alkermes Sinks as FDA Refuses Depression Drug Review Zacks |
Apr-02-18 10:25AM | Edge Therapeutics Loses Edge on Failure of Late-Stage Study Zacks |
Mar-28-18 07:30AM | Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2018 Business Wire |
Mar-22-18 10:00AM | Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead? Zacks |
Mar-21-18 09:59AM | Novo Nordisk Poised on Strong Pipeline Amid Competition Zacks |
Mar-16-18 09:47AM | Alexion (ALXN) Gains On Positive Date From Lead Candidate Zacks |
08:42AM | ArQule (ARQL) in Focus: Stock Moves 15.6% Higher Zacks |
Mar-15-18 12:03PM | Catalyst (CPRX) Posts In-Line Q4 Loss, Pipeline in Progress Zacks |
10:45AM | Arena Pharmaceuticals (ARNA) Q4 Earnings Beat, Sales Down Y/Y Zacks |
Mar-12-18 11:25AM | Aradigm Files MAA for Bronchiectasis Candidate in the EU Zacks |
08:58AM | Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump Zacks |
Mar-09-18 09:22AM | Pfizer Gets FDA Panel Backing for New Indication for Xeljanz Zacks |
Mar-08-18 07:24PM | Corcept Plans Korlym Label Expansion, Pipeline in Progress Zacks |
06:02AM | Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing Zacks |
06:01AM | Lilly, Boehringer to Expand Jardiance Heart Failure Program Zacks |
Mar-06-18 10:36AM | Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink Zacks |
07:30AM | Enanta Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference Business Wire |
Mar-02-18 02:33PM | Pacira (PCRX) Posts Earnings in Q4, Revenues in Line Zacks |
02:29PM | Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress Zacks |
12:12PM | Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y Zacks |
10:53AM | Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y Zacks |
Feb-28-18 12:55PM | Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4 Zacks |
09:29AM | Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y Zacks |
09:09AM | AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues Zacks |
Feb-27-18 09:53AM | Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down Zacks |
08:54AM | Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4 Zacks |
Feb-23-18 08:55AM | Corcept's (CORT) Earnings and Sales Meet Estimates in Q4 Zacks |
Feb-19-18 10:04AM | AbbVie Presents New Data on Upadacitinib for Crohn's Disease Zacks |
|
|
|
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Gardiner Nathaniel S. | Sr. VP & General Counsel | Feb 13 | Sale | 95.28 | 3,270 | 311,562 | 23,978 | Feb 13 09:28 PM | CARTER BRUCE L A | Director | Feb 12 | Option Exercise | 23.40 | 5,000 | 117,000 | 5,000 | Feb 13 08:50 PM | Golumbeski George | Director | Feb 12 | Option Exercise | 27.88 | 11,228 | 313,012 | 11,228 | Feb 13 08:57 PM | Golumbeski George | Director | Feb 12 | Sale | 90.07 | 11,228 | 1,011,301 | 0 | Feb 13 08:57 PM | CARTER BRUCE L A | Director | Feb 12 | Sale | 90.00 | 5,000 | 450,000 | 0 | Feb 13 08:50 PM | Or Yat Sun | Sr. VP & CSO | Feb 12 | Sale | 90.07 | 6,297 | 567,173 | 301,916 | Feb 13 09:11 PM | Or Yat Sun | Sr. VP & CSO | Feb 11 | Option Exercise | 13.18 | 25,977 | 342,402 | 335,897 | Feb 13 09:11 PM | CARTER BRUCE L A | Director | Feb 11 | Option Exercise | 23.40 | 2,734 | 63,976 | 2,734 | Feb 13 08:50 PM | Golumbeski George | Director | Feb 11 | Option Exercise | 25.58 | 2,272 | 58,118 | 2,272 | Feb 13 08:57 PM | Golumbeski George | Director | Feb 11 | Sale | 90.03 | 2,272 | 204,552 | 0 | Feb 13 08:57 PM | CARTER BRUCE L A | Director | Feb 11 | Sale | 90.02 | 2,734 | 246,102 | 0 | Feb 13 08:50 PM | Or Yat Sun | Sr. VP & CSO | Feb 11 | Sale | 89.39 | 27,684 | 2,474,737 | 308,213 | Feb 13 09:11 PM | Gardiner Nathaniel S. | Sr. VP & General Counsel | Jan 22 | Option Exercise | 34.70 | 2,000 | 69,400 | 17,827 | Jan 24 05:21 PM | Gardiner Nathaniel S. | Sr. VP & General Counsel | Dec 06 | Option Exercise | 34.70 | 2,000 | 69,400 | 15,827 | Dec 06 08:35 PM | Ocain Tim | Senior Vice President | Dec 03 | Option Exercise | 32.27 | 2,000 | 64,540 | 8,127 | Dec 04 05:42 PM | Ocain Tim | Senior Vice President | Oct 01 | Option Exercise | 24.90 | 25,000 | 622,400 | 31,127 | Oct 02 04:22 PM | Gardiner Nathaniel S. | Sr. VP & General Counsel | Oct 01 | Option Exercise | 34.70 | 1,500 | 52,050 | 13,827 | Oct 02 04:20 PM | Ocain Tim | Senior Vice President | Oct 01 | Sale | 83.64 | 25,000 | 2,090,903 | 6,127 | Oct 02 04:22 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Sep 20 | Option Exercise | 43.46 | 2,955 | 128,424 | 4,155 | Sep 21 04:18 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Sep 20 | Sale | 95.32 | 4,155 | 396,036 | 0 | Sep 21 04:18 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Aug 20 | Option Exercise | 43.46 | 2,955 | 128,424 | 4,465 | Aug 21 06:02 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Aug 20 | Sale | 92.32 | 4,155 | 383,596 | 310 | Aug 21 06:02 PM | Luly Jay R. | President and CEO | Jul 27 | Option Exercise | 11.77 | 8,498 | 99,990 | 601,524 | Jul 30 04:57 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Jul 18 | Option Exercise | 43.46 | 2,955 | 128,424 | 6,555 | Jul 19 04:35 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Jul 18 | Sale | 124.84 | 5,045 | 629,843 | 1,510 | Jul 19 04:35 PM | Luly Jay R. | President and CEO | Jul 06 | Sale | 125.38 | 32,023 | 4,014,892 | 593,026 | Jul 09 04:56 PM | Luly Jay R. | President and CEO | Jul 05 | Sale | 123.81 | 2,977 | 368,568 | 625,049 | Jul 09 04:56 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Jun 18 | Option Exercise | 43.46 | 2,955 | 128,424 | 7,755 | Jun 19 05:13 PM | MELLETT PAUL J | Treasurer and CFO | Jun 18 | Option Exercise | 1.98 | 6,960 | 13,799 | 80,418 | Jun 20 04:22 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Jun 18 | Sale | 114.85 | 4,155 | 477,222 | 3,600 | Jun 19 05:13 PM | MELLETT PAUL J | Treasurer and CFO | Jun 11 | Sale | 120.57 | 15,000 | 1,808,523 | 73,458 | Jun 12 05:32 PM | Luly Jay R. | President and CEO | May 17 | Sale | 105.83 | 10,968 | 1,160,742 | 628,026 | May 18 06:02 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | May 16 | Option Exercise | 43.46 | 2,955 | 128,424 | 8,955 | May 18 05:53 PM | Luly Jay R. | President and CEO | May 16 | Sale | 105.82 | 14,032 | 1,484,913 | 638,994 | May 18 06:02 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | May 16 | Sale | 105.25 | 4,155 | 437,333 | 4,800 | May 18 05:53 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Apr 16 | Option Exercise | 43.46 | 2,955 | 128,424 | 10,225 | Apr 18 05:34 PM | Adda Nathalie | Sr. VP & Chief Medical Officer | Apr 16 | Sale | 85.58 | 4,225 | 361,560 | 6,000 | Apr 18 05:34 PM | MELLETT PAUL J | Treasurer and CFO | Mar 19 | Sale | 86.48 | 9,000 | 778,331 | 88,458 | Mar 20 06:39 PM |
|